Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial

American Journal of Geriatric Psychiatry

Volumn 23, Issue 12, 2015, Pages 1214-1224

  Van Den Elsen, Geke A H ^a   Ahmed, Amir I A ^a,b   Verkes, Robbert Jan ^a   Feuth, Ton ^a   Van Der Marck, Marjolein A ^a   Olde Rikkert, Marcel G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

Author keywords

Key Words Dementia; neuropsychiatric symptoms; randomized controlled trial; tetrahydrocannabinol

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NOOTROPIC AGENT; PLACEBO; TETRAHYDROCANNABINOL; DRONABINOL; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; BEHAVIOR DISORDER; CAREGIVER BURDEN; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EAR DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; URINARY TRACT INFECTION; VASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; MENTAL DISORDERS; MULTICENTER STUDY; NETHERLANDS; PHASE 2 CLINICAL TRIAL; PSYCHOLOGY; TREATMENT OUTCOME;

AGED; CROSS-OVER STUDIES; DEMENTIA; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; HUMANS; MALE; MENTAL DISORDERS; NETHERLANDS; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 84975318325     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2015.07.011     Document Type: Article

References (36)

1. M. Steinberg, H. Shao, P. Zandi, and et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study Int J Geriatr Psychiatry 23 2008 170 177
2. S. Banerjee, S.C. Smith, D.L. Lamping, and et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia J Neurol Neurosurg Psychiatry 77 2006 146 148
3. K. Levy, K.L. Lanctot, S.B. Farber, and et al. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? Drugs Aging 29 2012 167 179
4. K. Hooker, S.R. Bowman, D.P. Coehlo, and et al. Behavioral change in persons with dementia: relationships with mental and physical health of caregivers J Gerontol B Psychol Sci Soc Sci 57 2002 P453 P460
5. M.E. de Vugt, F. Stevens, P. Aalten, and et al. A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia Int Psychogeriatr 17 2005 577 589
6. J. Cummings, J. Mintzer, H. Brodaty, and et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition Int Psychogeriatr 27 2015 7 17
7. S.U. Zuidema, E. Derksen, F.R. Verhey, and et al. Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia Int J Geriatr Psychiatry 22 2007 632 638
8. R.B. Wetzels, S.U. Zuidema, J.F. de Jonghe, and et al. Prescribing pattern of psychotropic drugs in nursing home residents with dementia Int Psychogeriatr 23 2011 1249 1259
9. C. Ballard, and A. Corbett Agitation and aggression in people with Alzheimer's disease Curr Opin Psychiatry 26 2013 252 259
10. C.G. Ballard, S. Gauthier, J.L. Cummings, and et al. Management of agitation and aggression associated with Alzheimer disease Nature Rev Neurol 5 2009 245 255
11. S. Gauthier, J. Cummings, C. Ballard, and et al. Management of behavioral problems in Alzheimer's disease Int Psychogeriatr 22 2010 346 372
12. A.P. Porsteinsson, L.T. Drye, B.G. Pollock, and et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial JAMA 311 2014 682 691
13. S. Walther, R. Mahlberg, U. Eichmann, and et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia Psychopharmacology 185 2006 524 528
14. L. Volicer, M. Stelly, J. Morris, and et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease Int J Geriatr Psychiatry 12 1997 913 919
15. T. Wang, J.P. Collet, S. Shapiro, and et al. Adverse effects of medical cannabinoids: a systematic review CMAJ 178 2008 1669 1678
16. G.A. van den Elsen, A.I. Ahmed, M. Lammers, and et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review Ageing Res Rev 14 2014 56 64
17. L.E. Klumpers, T.L. Beumer, J.G. van Hasselt, and et al. Novel Delta(9)-tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects Br J Clin Pharmacol 74 2012 42 53
18. G.M. McKhann, D.S. Knopman, H. Chertkow, and et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alz Dement 7 2011 263 269
19. G.C. Roman, T.K. Tatemichi, T. Erkinjuntti, and et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 43 1993 250 260
20. J.L. Cummings The Neuropsychiatric Inventory: assessing psychopathology in dementia patients Neurology 48 1997 S10 S16
21. Z. Ismail, C.A. Emeremni, P.R. Houck, and et al. A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia Am J Geriatr Psychiatry 21 2013 78 87
22. J. Cohen-Mansfield Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument Int Psychogeriatr 8 suppl 3 1996 309 315 discussion 351-304
23. M. Bedard, D.W. Molloy, L. Squire, and et al. The Zarit Burden Interview: a new short version and screening version Gerontologist 41 2001 652 657
24. M.E. Tinetti Performance-oriented assessment of mobility problems in elderly patients J Am Geriatr Soc 34 1986 119 126
25. D. Podsiadlo, and S. Richardson The timed "Up & Go": a test of basic functional mobility for frail elderly persons J Am Geriatr Soc 39 1991 142 148
26. K.E. Webster, J.E. Wittwer, and J.A. Feller Validity of the GAITRite walkway system for the measurement of averaged and individual step parameters of gait Gait Posture 22 2005 317 321
27. J.H. Allum, and M.G. Carpenter A speedy solution for balance and gait analysis: angular velocity measured at the centre of body mass Curr Opin Neurol 18 2005 15 21
28. T.A. Bowdle, A.D. Radant, D.S. Cowley, and et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations Anesthesiology 88 1998 82 88
29. A.C. Scheffer, B.C. van Munster, M.J. Schuurmans, and et al. Assessing severity of delirium by the Delirium Observation Screening Scale Int J Geriatr Psychiatry 26 2011 284 291
30. R. Ihl, N. Bachinskaya, A.D. Korczyn, and et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial Int J Geriatr Psychiatry 26 2011 1186 1194
31. M.S. Mega, D.M. Masterman, S.M. O'Connor, and et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease Arch Neurol 56 1999 1388 1393
32. J.C. Morris, P.A. Cyrus, J. Orazem, and et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease Neurology 50 1998 1222 1230
33. L. Zuurman, C. Roy, R.C. Schoemaker, and et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans J Psychopharmacol 22 2008 707 716
34. S. Walther, B. Schupbach, E. Seifritz, and et al. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia J Clin Psychopharmacol 31 2011 256 258
35. M.R. Woodward, D.G. Harper, A. Stolyar, and et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms Am J Geriatr Psychiatry 22 2014 415 419
36. R.J. Howard, E. Juszczak, C.G. Ballard, and et al. Donepezil for the treatment of agitation in Alzheimer's disease N Engl J Med 357 2007 1382 1392